← Back to Search

Escape for Smoking

N/A
Waitlist Available
Led By Mary E. Cooley, PhD
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing the ESCAPE program to see if it can help women with HIV quit smoking and improve their lung health.

Who is the study for?
This trial is for high-risk smokers aged 55-77 who smoke at least 5 cigarettes a day and have a history of heavy smoking (≥30 pack years). Participants must be English-speaking, own a mobile phone with video call capability, have active health insurance, and can complete an interview. They should not have had lung cancer or low-dose CT screening before.
What is being tested?
The study compares the ESCAPE program—a smoking cessation approach that includes education on lung screening—to standard care. The goal is to see if adding lung screening information helps people quit smoking more effectively and improves their overall lung health.
What are the potential side effects?
Since this trial focuses on behavioral intervention rather than medication, traditional side effects are not expected. However, participants may experience stress or anxiety related to quitting smoking or from changes in behavior due to the program.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
7-day point prevalence smoking cessation rate
Malignant Neoplasms
number of cigarettes smoked/day
Secondary study objectives
Completion rate
Narrative Engagement Scale scores
Percentage of the group indicate that the film would have value to others
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Standard CareExperimental Treatment1 Intervention
The usual care program will include 1 counseling session, nicotine replacement therapy at no cost referral and enrollment in quitworks and an educational brochure about lung cancer screening
Group II: EscapeExperimental Treatment1 Intervention
The ESCAPE program provides 8 counseling sessions over the phone, provides nicotine replacement therapy at no cost, and education about lung screening

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor
1,108 Previous Clinical Trials
357,084 Total Patients Enrolled
American Association for Cancer ResearchOTHER
8 Previous Clinical Trials
679 Total Patients Enrolled
Mary E. Cooley, PhDPrincipal Investigator - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
1 Previous Clinical Trials
179 Total Patients Enrolled

Media Library

ESCAPE Clinical Trial Eligibility Overview. Trial Name: NCT04691297 — N/A
Tobacco Smoking Research Study Groups: Standard Care, Escape
Tobacco Smoking Clinical Trial 2023: ESCAPE Highlights & Side Effects. Trial Name: NCT04691297 — N/A
ESCAPE 2023 Treatment Timeline for Medical Study. Trial Name: NCT04691297 — N/A
~32 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top